TABLE 6.

Clinical parameters of patients developing DSA.

Months from transplantation	Organ	HLA	Subtype	Time from baseline to anti-HLA determination	Increase in MFI from baseline (%)	Rejection	Outcome
57	Combined Liver-Kidney	Class I	HLA I-A 01:01	5 weeks	−83.1%	No	Favorable
14	Kidney	Class II	HLA II DRB1*01:03	10 weeks	−40.2%	No	Favorable
52	Lung	Class II	HLA II DR52	1 year	37.4%	No	Favorable
49	Lung	Class II	HLA II DQ9, DQ2	1 year	83.55%	No	Favorable
6	Kidney	Class II	HLA DQ7, DQ4	1 year	Undetectable at baseline	No	Favorable